Pulmonary surfactant: a mighty thin film

F Possmayer, YY Zuo, RAW Veldhuizen… - Chemical …, 2023 - ACS Publications
Pulmonary surfactant is a critical component of lung function in healthy individuals. It
functions in part by lowering surface tension in the alveoli, thereby allowing for breathing …

Exogenous pulmonary surfactant: A review focused on adjunctive therapy for severe acute respiratory syndrome coronavirus 2 including SP-A and SP-D as added …

A Ghati, P Dam, D Tasdemir, A Kati, H Sellami… - Current opinion in …, 2021 - Elsevier
Type I and type II pneumocytes are two forms of epithelial cells found lining the alveoli in the
lungs. Type II pneumocytes exclusively secrete 'pulmonary surfactants,'a lipoprotein …

[HTML][HTML] Surfactant therapy for COVID-19 related ARDS: a retrospective case–control pilot study

S Piva, RM DiBlasi, AE Slee, AH Jobe, AM Roccaro… - Respiratory …, 2021 - Springer
Background COVID-19 causes acute respiratory distress syndrome (ARDS) and depletes
the lungs of surfactant, leading to prolonged mechanical ventilation and death. The …

Computational lung modelling in respiratory medicine

S Neelakantan, Y Xin, DP Gaver… - Journal of The …, 2022 - royalsocietypublishing.org
Computational modelling of the lungs is an active field of study that integrates computational
advances with lung biophysics, biomechanics, physiology and medical imaging to promote …

The COVID-19 pandemic: a target for surfactant therapy?

RAW Veldhuizen, YY Zuo, NO Petersen… - Expert review of …, 2021 - Taylor & Francis
Introduction The dramatic impact of COVID-19 on humans worldwide has initiated an
extraordinary search for effective treatment approaches. One of these is the administration of …

Surfactant-mediated wetting and spreading: Recent advances and applications

NM Kovalchuk, MJH Simmons - Current Opinion in Colloid & Interface …, 2021 - Elsevier
Surfactant-mediated wetting and spreading are ubiquitous. Understanding of these
phenomena in-depth allows precise tailoring of wetting performance which can contribute to …

[HTML][HTML] Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps

D De Luca, P Cogo, MC Kneyber, P Biban, MG Semple… - Critical Care, 2021 - Springer
Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have
different age-specific characteristics and definitions. Trials on surfactant for ARDS in children …

[HTML][HTML] Pulmonary surfactant in adult ARDS: current perspectives and future directions

A Dushianthan, MPW Grocott, GS Murugan… - Diagnostics, 2023 - mdpi.com
Acute respiratory distress syndrome (ARDS) is a major cause of hypoxemic respiratory
failure in adults, leading to the requirement for mechanical ventilation and poorer outcomes …

Constant Vt Ventilation and Surfactant Dysfunction: An Overlooked Cause of Ventilator-induced Lung Injury

RK Albert - American Journal of Respiratory and Critical Care …, 2022 - atsjournals.org
Ventilator-induced lung injury (VILI) is currently ascribed to volutrauma and/or atelectrauma,
but the effect of constant Vt ventilation (CVtV) has received little attention. This Perspective …

[HTML][HTML] Co-aerosolized pulmonary surfactant and ambroxol for COVID-19 ARDS intervention: what are we waiting for?

P Kumar - Frontiers in Bioengineering and Biotechnology, 2020 - frontiersin.org
After more than 225 days of the first reports of the novel coronavirus from China, COVID-19
pandemic is still on surge. The search for an effective and efficient therapeutic and …